Table 3.

Candidate prognostic indicators for survival to 6 months after diagnosis in 94 cats with histoplasmosis treated with antifungal therapy

Candidate indicator	Survivors (n = 63)	Non-survivors (n = 31)	P value
Clinical findings
Age (years)	7.0 (6.0)	6.0 (6.0)	0.71
Weight (kg)	3.6 (1.6)	3.3 (1.3)	0.82
Duration of clinical signs (weeks)	7.0 (17.0)	4.0 (10.0)	0.41
Weight loss (% with sign)	81	97	0.05
Diarrhea (% with sign)	8	19	0.17
Dyspnea (% with sign)	52	71	0.12
Lameness (% with sign)	19	3	0.05
Adventitial lung sounds (% with finding)	35	48	0.26
Lymphadenopathy (% with finding)	35	26	0.48
Abdominal organomegaly (% with finding)	22	32	0.32
Cutaneous lesions (% with finding)	16	10	0.53
Joint effusion (% with finding)	9	0	0.17
Body temperature (ºF)	102.3 (2.0)	101.8 (1.4)	0.04
Respiratory rate (breaths/min)	44 (28)	46 (36)	0.52
Form (% with form)*	71/19/10	77/19/3	0.55
Neurologic disease (% with finding)	0	10	0.03
Fungemia (% with finding)	3	19	0.01
Thrombocytopenia (% with finding)	43	52	0.58
Multiple cytopenias (% with finding) †	15	39	0.02
Treatment
Initial antifungal treatment (% fluconazole)	49	27	0.09
Fluconazole start dose (mg/kg/day)	14.3 (11.1)	18.9 (9.3)	0.29
Itraconazole start dose (mg/kg/day)	10.0 (0.9)	9.7 (4.8)	0.04
Glucocorticoid treatment (% did receive)	44	63	0.12
Glucocorticoid dose (mg/kg/day) ‡	0.82 (0.57)	0.59 (0.47)	0.31
Oxygen supplementation (% did require)	19	55	<0.001
Hospitalization (% did require)	49	81	0.003
Hospitalization duration (days)	0 (3.0)	3.0 (5.0)	0.01

Values in bold are P ⩽0.05. Data are median (interquartile range [75th percentile–25th percentile]) or n (%), unless otherwise indicated

^*Disseminated/respiratory/gastrointestinal

^†Defined as at least two of the following: anemia, neutropenia, thrombocytopenia

^‡Prednisolone dose or prednisolone equivalent (dexamethasone dose • 7)